A New Therapeutic Target: Bruton Tyrosine Kinase Inhibition in the treatment of urticaria and pemphigus

Abstract

Bruton tyrosine kinase (BTK), a member of the tyro sineprotein kinase Tec family, is a cytoplasmic, non-receptor kinase that plays a key role in numerous immunological pathways. BTK activity is particularly crucial in B-cell development, migration, and activation through B-cell receptor activation. Additionally, BTK is critical for receptor-mediated signal transduction involving Fc receptors, Toll-like receptors, and chemokine receptors. Due to its dual role in innate and adaptive immunity, BTK inhibition represents a promising therapeutic target for immune-mediated dermatological disorders. The potential applications of BTK inhibitors in dermatology have gained increasing attention, with a particular focus on the treatment of chronic spontaneous urticaria and pemphigus vulgaris.